Immutep

Entering Phase I

lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in Melanoma

Orsay, September 25, 2006, lmmutep S.A. announced today that its lead product, ImmuFact® IMP321, has entered a Phase I clinical trial in disease-free melanoma. ImmuFact IMP321 is a potent natural human T celI immunostimulatory factor designed to amplify the Tcell immune response. It can be used either as an immunopotentiator in therapeutic vaccines or alone in monotherapy or in combination with chemotherapy.

The Cancer Centre at the St Luc University Clinic, Brussels, is conducting the clinical trial.The design is a randomised open-label four-arm trial comparing a selected set of 8 HLA-A2 melanoma peptide antigens with or without IMP321 and/or Montanide. The study is being carried out by Dr. Jean-François Baurain as Principal Investigator and Pr. Pierre Coulie (Université Catholique de Louvain) for the immunomonitoring part of the study. Most of these HLA-A2 melanoma peptide antigens were first discovered by Pr. Thierry Boon’s team at the Ludwig Institute for Cancer Research in Brussels, a world-class leading group in the field of cancer vaccines.

Please, click on ADOBE PDF logo to read the complete communique.

Published 10/2006 by admin@immutep.com